Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes

Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes

Abstract Type 2 diabetes significantly increases cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events, heart failure hospitalizations, and death. However, the comparison among GLP-1 RAs on cardiovascular outcomes is limited. We compared...

Full description

Saved in:
Bibliographic Details
Main Authors: Takefumi Kishimori, Takao Kato, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Yoshihiro Iwasaki, Takehiro Matsumoto, Takafumi Yagi, Masaharu Okada
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-06245-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items